DJIA 17,141.96 110.82 0.65%
NASDAQ 4,554.86 35.96 0.80%
S&P 500 2,000.04 15.91 0.80%
market minute promo

Novo Nordisk (NYSE: NVO)

company name or ticker
Company Photos
(Click to zoom)

Sanofi's Basal Insulin Candidate Under FDA Review - Analyst Blog

Novo Nordisk Gets FDA Nod for NovoSeven RT - Analyst Blog

Can Dividend Stocks Novo Nordisk and Novartis Continue to Perform?

Dividends and growth -- watch below to learn more about these stocks

1 Key Question Remains after MannKind's Giant Leap

After FDA approval, now comes the hard part

3 Things to Look for in MannKind's Partnership

Merck would be a perfect partner for MannKind; Novo Nordisk and Eli Lilly are likely out.

MannKind Is Still a Risky Investment Even With FDA Approval

MannKind Stock: Afrezza Approved at Last, But Will Sales Disappoint?

MannKind finally got its approval for inhaled insulin, but the marketing challenges are only beginning.

MannKind's Afrezza Approved but Will Doctors Prescribe It?

MannKind is going to have a hard time competing with Novo Nordisk and Eli Lilly, especially in type 1 diabetics.

Up 9%: What You Need to Know About MannKind Today

MannKind's Afrezza is approved but can it compete with injected insulin from Novo Nordisk and Eli Lilly?

Consider Shire Pharmaceuticals Now; 20%+ Upside Left In Takeover Bid By AbbVie

See More Articles...